International Anal Neoplasia Society's consensus guidelines for anal cancer screeningElizabeth A. Stier, Naomi Jay, Luis F. Barroso et al.|International Journal of Cancer|2024Cited by 267
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USAPrajakta P. Masurkar, Meghana V. Trivedi, Haluk Damgacioglu et al.|PharmacoEconomics|2023Cited by 25
Prevalence and Risk of Penile Human Papillomavirus Infection: Evidence From The National Health and Nutrition Examination Survey 2013–2014Ashish A. Deshmukh, Arch G. Mainous|Clinical Infectious Diseases|2017Cited by 21
Abstract 891: Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2- metastatic breast cancer in postmenopausal women in the United StatesPrajakta P. Masurkar, Meghana V. Trivedi, Haluk Damgacioglu et al.|Cancer Research|2021Cited by 3
Abstract 4364: Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+/HER2-, node-positive, high-risk, early breast cancerAshna Talwar, Rajender R. Aparasu, Ashish A. Deshmukh et al.|Cancer Research|2023Cited by 3